Shanghai Bao Pharmaceuticals Co., Ltd.

上海宝济药业股份有限公司

02659.HK

Biotechnology company founded in 2019 developing engineered enzymes for large-volume subcutaneous drug delivery, IgG-mediated autoimmune diseases, assisted reproduction, and recombinant biologic products in China. Core pipeline includes recombinant human hyaluronidase KJ017 and IgG-degrading enzyme KJ103.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Customer concentration
• Supplier concentration
• Overlapping customers and suppliers
• Reliance on platforms, partners or licences
• Outsourced production (OEM / contract manufacturing)
• Capacity and utilisation
• Losses and path to profitability
• Negative operating cash flow
• Cash burn and runway
• Adverse change after the track record
• Non-IFRS measures and adjustments
• Non-recurring gains and losses
• Related-party transactions and balances
• Material share-based payments
• Chapter 18A biotech